Overview

HD16 for Early Stage Hodgkin Lymphoma

Status:
Active, not recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This study is designed to test the non-inferiority of the experimental arm compared to the standard arm in terms of Progression free survival (PFS).
Phase:
Phase 3
Details
Lead Sponsor:
University of Cologne
Treatments:
Bleomycin
Dacarbazine
Doxorubicin
Liposomal doxorubicin
Vincristine